# CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

> **NCT00812669** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 52 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** pegfilgrastim
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **GENETIC:** cytogenetic analysis
- **GENETIC:** fluorescence in situ hybridization
- **GENETIC:** gene expression analysis
- **GENETIC:** mutation analysis
- **GENETIC:** protein expression analysis
- **OTHER:** flow cytometry
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00812669
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-18
- **Primary completion:** 2019-11-21
- **Final completion:** 2019-11-21
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00812669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00812669, "CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00812669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*